MSHLBevacizumab Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
1) Atezolizumab in combination with bevacizumab (non-subsidised brand) and platinum-doublet chemotherapy, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC.
2) Atezolizumab in combination with bevacizumab (non-subsidised brand) for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.